Friends of Cancer Research (Friends) is excited to announce its latest publication “Homologous Recombination Deficiency: Concepts, Definitions, and Assays.” Findings from this manuscript set the foundation for the ongoing Homologous Recombination Deficiency (HRD) Harmonization Project, a unique research partnership focused on developing strategies to assess assay performance and align on methods for measuring and using…
Washington, DC – Friends of Cancer Research (Friends) is pleased to announce findings from the final analysis of our TMB Harmonization Project published this week in Annals of Oncology, “Aligning Tumor Mutational Burden (TMB) quantification across diagnostic platforms: Phase 2 of the Friends of Cancer Research TMB Harmonization Project.” Tumor mutational burden, or TMB, is…
New ASCO-Friends Joint Position Statement Encourages Enrollment of Patients with Cancer in Vaccine Studies Alexandria, Va. and Washington, DC. – Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research…
Washington, DC – June 8, 2021 – Friends of Cancer Research (Friends) is proud to announce the launch of Step 2 of the ctDNA for Monitoring Treatment Response (ctMoniTR) Project. This project aims to determine the extent to which changes in circulating tumor DNA (ctDNA) are an early indicator of response to therapy on a larger…
Washington, DC – April 12, 2021 – Friends of Cancer Research would like to congratulate Dr. Patrizia Cavazzoni for being named the director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). “The naming of Dr. Cavazzoni as director of CDER at FDA by Acting Commissioner Woodcock…
Washington, DC – January 20, 2021 – Friends of Cancer Research (Friends) would like to applaud President Biden for selecting Dr. Janet Woodcock to serve as acting Commissioner of the U.S. Food and Drug Administration (FDA). We look forward to working with Dr. Woodcock in her new role as the acting lead at the FDA,…
Bipartisan MODERN Labeling Act Included Washington, DC – December 22, 2020 – Friends of Cancer Research (Friends) applauds the bipartisan work of the House and Senate to bolster the U.S. economy and support patients, physicians, and families during the COVID-19 pandemic. We would also like to acknowledge the strong bipartisan work of the Members and…
Washington, DC – December 2, 2020 – Friends of Cancer Research (Friends) praises the scientific endeavor that has unfolded during the past months to discover a safe and effective vaccine against the novel coronavirus (COVID-19). It has been no small feat and could not have been achieved as quickly and safely as it has without…
Washington, DC – Today, the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, announce the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder, collaborative project to leverage real-world data in the diagnostic test (e.g., nucleic acid or antigenic) and antibody test (e.g., serological) study space. Bringing together device manufacturers, technology companies, government and…
Today, Friends of Cancer Research (Friends) released the findings from Phase 2 of its TMB Harmonization Project at the AACR Virtual Annual Meeting I. These results are the outcome of the large-scale project led by Friends, which is leading the standardization of tumor mutational burden (TMB) calculation and reporting, in order to more effectively evaluate…
